MedPage Today on MSN1d
Newer Biologics Tied to Fewer Infections for Older Patients With Psoriatic Disease
IL-23, and IL-17 were associated with a lower rate of serious infections among older adults with psoriatic disease, a ...
Medical Dialogues3d
Synokem Pharmaceutical Gets CDSCO Panel Nod To study Tofacitinib Extended Release Tablets
New Delhi: Synokem Pharmaceutical has got approval from the Subject Expert Committee (SEC) functional under the Central Drug ...
Hosted on MSN2mon
Tofacitinib reduces SARS-CoV-2 infection risk in patients with PTPN2 deficiency
Study: Tofacitinib Mitigates the Increased SARS-CoV-2 Infection Susceptibility Caused by an IBD Risk Variant in the PTPN2 Gene. Image Credit: GB.JSTOCK / Shutterstock.com A recent study published ...
The American Journal of Managed Care3d
Biologics Linked to Lower Infection Risk in Older Adults With Psoriatic Disease
IL-23, or IL-17 reduced serious infections, while tofacitinib increased infection risk, according to one study.